Samsara BioCapital related stories
All articles and analysis
Alpheus Medical inks $52m Series BHealthQuest Capital and Samsara BioCapital led the round.
Alpha-9 Oncology nabs $175m Series CLightspeed Venture Partners and Ascenta Capital led the round.
- ImmunOs Therapeutics picks up Series B
ImmunOs Therapeutics AG, a biopharmaceutical company, has raised $74 million in Series B financing.
- Tentarix lands $50m Series A round led by Versant, Samsara
San Diego and Vancouver-based biotechnology company Tentarix Biotherapeutics secured $50 million in Series A financing.
Neurogastrx rakes in $60m Series BNeurogastrx, a developer of treatments for gastrointestinal disorders, has secured $60 million in Series B funding.
- Prime Medicine gathers $200m Series B
Prime Medicine, a biotech company, has raised $200 million in Series B funding.
- VC-backed Graphite Bio raises $238m for IPO
Graphite Bio, a gene editing company focused on treating or curing serious diseases, has raised $238 million for its IPO after pricing its 14 million shares at $17 per share.
Janux Therapeutics goes publicJanux Therapeutics, a biopharmaceutical company, has raised $193.8 million for its IPO after pricing its 11.4 million shares at $17 per share.
Rain Therapeutics raises $125m for IPORain Therapeutics, a developer of precision oncology therapeutics, has raised about $125 million for its IPO after pricing its over 7.3 million shares at $17 per share.
- Tango Therapeutics to go public via merger with Boxer Capital-backed SPAC
Tango Therapeutics, a biotech company, has agreed to go public via a merger with BCTG Acquisition Corp, a blank check company backed by Boxer Capital.